Nektar Pins Falling Cancer Response Rate On Manufacturing Problem
A post-hoc analysis linked “physical differences” in two lots of Nektar’s drug to lower efficacy when given in combination with Bristol-Myers Squibb’s Opdivo. Nektar’s share price tumbled following the update.
You may also be interested in...
Nektar Restructuring Ends Bempeg Ambitions, Cuts Staff By 70%
Following termination of its immuno-oncology partnership with Bristol, Nektar is paring operations, closing its India site and focusing on mid-stage NKTR-358, partnered with Lilly, and NKTR-255.
Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders
Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.
Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.